In last trading session, Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw 1,807,222 shares changing hands with its beta currently measuring 3.56. Company’s recent per share price level of $1.94 trading at -$0.19 or -9.13% at ring of the bell on the day assigns it a market valuation of $77.31 Million. That closing price of ALRN’s stock is at a discount of -13.4% from its 52-week high price of $2.2 and is indicating a premium of 87.11% from its 52-week low price of $0.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.51 Million shares which gives us an average trading volume of 889.12 Million if we extend that period to 3-months.
For Aileron Therapeutics, Inc. (ALRN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.4. Splitting up the data highlights that, out of 5 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 5 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.15 in the current quarter.
Aileron Therapeutics, Inc. (NASDAQ:ALRN) trade information
In the face of being in the red today for losing -9.13%, in the last five days ALRN remained trading in the green while hitting it’s week-highest on Wednesday, Oct 14 when the stock touched $2.2 price level, adding 11.82% to its value on the day. Aileron Therapeutics, Inc.’s shares saw a change of 238.57% in year-to-date performance and have moved 19.75% in past 5-day. Aileron Therapeutics, Inc. (NASDAQ:ALRN) showed a performance of 48.09% in past 30-days. Number of shares sold short was 756.54 Million shares which calculate 0.85 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $4.89 to the stock, which implies a rise of 152.06% to its current value. Analysts have been projecting $2 as a low price target for the stock while placing it at a high target of $8. It follows that stock’s current price would jump +312.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of 3.09% for stock’s current value.
Aileron Therapeutics, Inc. (ALRN) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.8% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 44.1% while estimates for its earnings growth in next 5 years are of 2.1%
Aileron Therapeutics, Inc. (NASDAQ:ALRN)’s Major holders
Insiders are in possession of 26.52% of company’s total shares while institution are holding 16.29% percent of that, with stock having share float percentage of 22.17%. Investors also watch the number of corporate investors in a company very closely, which is 24 institutions for Aileron Therapeutics, Inc. that are currently holding shares of the company. Renaissance Technologies, LLC is the top institutional holder at ALRN for having 1.38 Million shares of worth $1.63 Million. And as of June 29, 2020, it was holding 3.47% of the company’s outstanding shares.
The second largest institutional holder is Banco Bilbao Vizcaya Argentaria, SA, which was holding about 854.25 Thousand shares on June 29, 2020. The number of shares represents firm’s hold over 2.14% of outstanding shares, having a total worth of $1.01 Million.
On the other hand, PGIM Jennison Health Sciences Fd and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of August 30, 2020, the former fund manager was holding 895522 shares of worth $1.15 Million or 2.25% of the total outstanding shares. The later fund manager was in possession of 199.29 Thousand shares on June 29, 2020, making its stake of worth around $235.16 Thousand in the company or a holder of 0.5% of company’s stock.